New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
05:50 EDTRPRXRepros Therapeutics meets with FDA to discuss data requirements for Androlax
Repros Therapeutics announced the outcome of its previously announced meeting with the FDA regarding the Androxal Phase 3 data requirements for an NDA in the treatment of secondary hypogonadism. Repros expects to maintain its timeline for submitting an NDA prior to the end of 2014. This submission will include studies ZA-304 and ZA-305 which were initiated in January 2014. Following the meeting, the Company understands that the safety of Androxal will stand on its own merits during NDA review and no additional safety assessments are currently planned prior to NDA submission. The FDA requested additional background information regarding the endpoints that the company will use to confirm maintenance of fertility by semen assessments in studies ZA-304 and ZA-305. The company plans to provide this information promptly to the FDA and while doing so to continue enrollment of ZA-304 and ZA-305 without interruption.
News For RPRX From The Last 14 Days
Check below for free stories on RPRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
11:37 EDTRPRXHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use